导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.48% | 3395/4773 |
| 近一周 | -0.91% | 300/5462 |
| 近一月 | 2.44% | 273/5421 |
| 近一季 | 3.30% | 372/5209 |
| 近半年 | 0.28% | 1177/4920 |
| 近一年 | -4.63% | 3124/4366 |
| 近两年 | 31.77% | 2206/2954 |
| 近三年 | 23.32% | 1352/2253 |
| 成立以来 | 37.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.81% 4321/4961 |
-4.37% 3504/5312 |
- - |
- - |
| 2025 | 8.79% 2892/4813 |
-1.84% 2792/3635 |
8.01% 354/4076 |
-0.70% 3939/4524 |
3.33% 695/4813 |
| 2024 | 31.62% 93/3463 |
2.65% 736/2808 |
0.73% 552/3014 |
25.68% 296/3129 |
1.28% 1093/3463 |
| 2023 | -5.14% 718/2656 |
-1.01% 1841/2280 |
- 351/2385 |
4.59% 148/2515 |
-8.38% 2283/2655 |
| 2022 | -11.83% 259/2207 |
-5.06% 174/1919 |
-1.43% 1720/2016 |
-10.24% 367/2113 |
4.95% 499/2208 |
| 2021 | -8.20% 1047/1822 |
-1.40% 484/1255 |
-2.67% 1223/1330 |
-4.78% 736/1466 |
0.46% 1106/1822 |
| 2020 | 5.03% 887/1250 |
-13.80% 941/1028 |
4.24% 914/1067 |
9.85% 610/1164 |
6.41% 758/1184 |
| 2019 | 31.48% 466/1092 |
26.84% 374/739 |
0.63% 158/788 |
-3.13% 727/850 |
6.34% 624/918 |
| 2018 | - - |
- - |
- - |
10.39% 15/660 |
-9.02% 118/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 嘉实中证金融地产ETF联接C VS. 长安沪深300非周期A(740101) |